Sign In
Buy AUTL
$1.62
-0.130 (-7.43%)
At Close: Jun 03, 2026
Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript
04:37pm, Tuesday, 12'th Aug 2025
Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Amanda Cray - Corporate Participant Christian Martin Itin - CEO & Director Robe
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
07:00am, Tuesday, 12'th Aug 2025
Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025 Company recently received conditional marketing authorization from U.K. Medicines and
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
07:30am, Thursday, 24'th Jul 2025
LONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering n
Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity EC approval follows posi
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 15'th Jul 2025
LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering nex
Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow up More than half of patients still in remission at 24 months 38% of ongoing responders did not recei
Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market
11:09am, Friday, 06'th Jun 2025
Autolus Therapeutics plc is a UK-based biotech that has brought its ex-vivo CAR-T cell therapy to market in B-ALL with a "best-in-class" safety/efficacy profile. In this small indication, peak revenu
Autolus Therapeutics to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 29'th May 2025
LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programm
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-ALL
I Missed The Quantum Rally - I Won't Miss The Next One
05:47am, Tuesday, 20'th May 2025
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, progra
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
09:30am, Wednesday, 14'th May 2025
LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programm
Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript
04:22am, Sunday, 11'th May 2025
Autolus Therapeutics plc (NASDAQ:AUTL ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Amanda Cray – Executive Director-Investor Relations Christian Itin – Chief Exec
Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
07:00am, Thursday, 08'th May 2025
Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 million U.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for AUCATZYL® for th
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory
Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event
04:05pm, Wednesday, 23'rd Apr 2025
Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia (ALL), lupus nephritis (LN) a
